August 20, 2021 07:47 AM EDT

While figuring out post-CRL future for roxadustat, FibroGen celebrates Europe OK with Astellas

Amber Tong

The FDA may not be ready to approve FibroGen’s roxadustat before it sees another clinical trial, but the European Commission is swinging its doors wide …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

While figuring out post-CRL future for roxadustat, FibroGen celebrates Europe OK with Astellas

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

While fig­ur­ing out post-CRL fu­ture for rox­adu­s­tat, Fi­bro­Gen cel­e­brates Eu­rope OK with Astel­las

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

While figuring out post-CRL future for roxadustat, FibroGen celebrates Europe OK with Astellas